Exploring how brain stimulation affects movement intention

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the relationship between brain stimulation and movement intention using non-invasive techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Researchers will analyze neural activity through neuroimaging to understand how these interventions influence patients with psychogenic movement disorders and non-epileptic seizures. The study will also focus on developing new experimental paradigms and data analysis methods to enhance understanding of movement volition. The findings could lay the groundwork for future studies aimed at improving treatment for these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

(Healthy Controls)

* Fluent in English

(Patients with PMD or PNES):

* Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
* Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening

Exclusion Criteria:

* Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
* Chronic or progressive medical condition
* Any history of traumatic brain injury or significant head trauma
* Currently meets criteria for substance abuse or dependence
* History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
* Pregnancy
* Metal or devices in the head, including neurostimulators or metal foreign bodies
* Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
* Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
* Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
* Current diagnosis of any inflammatory or autoimmune disorder within last 6 months

PMD and PNES Patients

* Any history of traumatic brain injury or significant head trauma
* Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
* Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
* Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
* Metal or devices in the head, including neurostimulators or metal foreign bodies
* Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
* Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
* Recurrent visual hallucinations, within the past 6 months;
* History of significant uncontrollable movements of the head;
* Any clinically significant abnormality on vital signs

Where it's running

• New York University School of Medicine
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Biyu He, MD — NYU Langone Health
• Study coordinator: Nalini Jeet
• Email: Nalini.Jeet@nyulangone.org
• Phone: (212) 263-0228

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding and treating seizures in newborns

  This study is testing how genetic information can help doctors better understand and treat seizures in newborns during their first month of life.

  Recruiting Children's Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT03822741

• Levetiracetam to prevent seizures in adults with Down syndrome and Alzheimer's disease

  This trial will test whether the anti-seizure medicine levetiracetam can prevent tonic-clonic seizures and slow cognitive decline in adults over 40 who have Down syndrome and symptomatic Alzheimer's disease.

  Recruiting Phase 3 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Granada, Andalusia and 4 other locations · NCT07234695

• Recognizing seizures in the intensive care unit

  This project tests how well NHS neurophysiology scientists, neurologists, intensivists, and ICU nurses can identify seizures from digital video recordings of ICU events.

  Recruiting Nottingham University Hospitals NHS Trust · Nottingham, Nottinghamshire · NCT07136298

• Preventing first seizures with levetiracetam in patients with motor cortex brain metastases

  This test will try giving levetiracetam to adults with motor cortex brain metastases who have never had a seizure to see if it prevents a first seizure compared with not giving the drug.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07130786

• Preventing early seizures after traumatic brain injury

  This randomized study will test whether phenytoin, levetiracetam, or placebo best prevent early seizures in people hospitalized with moderate-to-severe traumatic brain injury.

  Recruiting at 3 sites Phase 4 All India Institute of Medical Sciences, Jodhpur · Chandigarh, Punjab and 2 other locations · NCT07072624

• Wearable device for detecting seizures

  This study tests a new wearable device for detecting seizures in people with epilepsy to see if it works well and can help them feel more comfortable in their daily lives.

  Recruiting at 2 sites University of Massachusetts, Worcester · Worcester, Massachusetts and 1 other locations · NCT06598189

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.